Long-Sheng Chang Selected Research

Acoustic Neuroma (Acoustic Neurinoma)

10/2021	Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
11/2017	Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
5/2017	Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
1/2016	Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
2/2012	Treatment of vestibular schwannoma cells with ErbB inhibitors.
1/2012	Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.
9/2011	AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
6/2009	Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
1/2008	Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.
3/2006	Cyclin D(1) and D(3) expression in vestibular schwannomas.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Long-Sheng Chang Research Topics

Disease

23	Neoplasms (Cancer) 10/2021 - 09/2002
13	Acoustic Neuroma (Acoustic Neurinoma) 10/2021 - 09/2002
12	Neurilemmoma (Schwannoma) 01/2021 - 09/2002
10	Meningioma (Meningiomas) 10/2021 - 09/2011
8	Neurofibromatosis 2 (Neurofibromatosis Type II) 10/2021 - 01/2002
5	Carcinogenesis 01/2018 - 09/2002
4	Neurofibrosarcoma (MPNST) 01/2020 - 06/2009
2	Neurofibromatoses (Neurofibromatosis) 10/2021 - 01/2018
2	Neurofibromatosis 1 (Neurofibromatosis Type I) 08/2012 - 09/2010
2	Neuroblastoma 05/2003 - 01/2002
1	Plexiform Neurofibroma 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Nervous System Neoplasms (Neoplasms, Nervous System) 11/2017
1	Ewing Sarcoma (Sarcoma, Ewing) 09/2010
1	Cysts 01/2008
1	Infertility (Sterility) 01/2008
1	Carcinoma (Carcinomatosis) 03/2006
1	Breast Neoplasms (Breast Cancer) 03/2006
1	Genetic Translocation (Chromosomal Translocation) 11/2003
1	Acute Erythroblastic Leukemia (Erythroleukemia) 11/2003

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 01/2018 - 09/2002
10	Neurofibromin 2 (Merlin)IBA 01/2019 - 12/2005
5	Pharmaceutical PreparationsIBA 10/2021 - 09/2011
4	Histone Deacetylase InhibitorsIBA 10/2021 - 09/2011
4	Phosphotransferases (Kinase)IBA 01/2021 - 02/2012
3	Eukaryotic Initiation Factor-4F (EIF4F)IBA 01/2020 - 01/2016
3	silvestrolIBA 01/2020 - 01/2016
3	LuciferasesIBA 01/2016 - 01/2002
3	RNA (Ribonucleic Acid)IBA 09/2002 - 01/2002
3	Complementary DNA (cDNA)IBA 09/2002 - 01/2002
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 01/2019
2	Eukaryotic Initiation Factor-4EIBA 01/2018 - 01/2016
2	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 10/2013
2	Neurofibromin 1 (Neurofibromin)IBA 08/2012 - 09/2010
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2012 - 01/2008
2	CyclinsIBA 03/2006 - 09/2002
2	ezrinIBA 12/2005 - 09/2002
1	brigatinibIBA 01/2021
1	AntioxidantsIBA 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	AZD 6244IBA 01/2021
1	Insulin (Novolin)FDA Link 01/2020
1	CaspasesIBA 01/2020
1	rocaglamideIBA 01/2020
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2019
1	trametinibIBA 01/2019
1	omipalisibIBA 01/2018
1	Dasatinib (BMS 354825)FDA Link 01/2018
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2018
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2018
1	PanobinostatIBA 01/2018
1	Carrier Proteins (Binding Protein)IBA 01/2018
1	Drug CombinationsIBA 01/2018
1	Peptide Initiation Factors (Initiation Factor)IBA 01/2018
1	Small Interfering RNA (siRNA)IBA 01/2018
1	EphA1 Receptor (Eph Receptor)IBA 01/2018
1	Eukaryotic Initiation Factor-4G (Eukaryotic Initiation Factor 4G)IBA 01/2018
1	TOR Serine-Threonine KinasesIBA 01/2018
1	cabozantinibIBA 11/2017
1	saracatinibIBA 11/2017
1	ponatinibIBA 05/2017
1	PhytochemicalsIBA 01/2016
1	Histones (Histone)IBA 01/2016
1	p21-Activated KinasesIBA 02/2015
1	FRAX597IBA 02/2015
1	furanoheliangolideIBA 10/2013
1	cucurbitacin DIBA 10/2013
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2013
1	NucleotidesIBA 01/2013
1	ras ProteinsIBA 08/2012
1	tyrosine receptor (receptor, tyrosine)IBA 02/2012
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2012
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2012
1	Lapatinib (GW572016)FDA Link 02/2012
1	ErbB Receptors (EGF Receptor)IBA 02/2012
1	Biological ProductsIBA 01/2012
1	MicroRNAs (MicroRNA)IBA 09/2010
1	Celecoxib (Celebrex)FDA Link 06/2009
1	Phosphatidylinositols (Phosphatidylinositol)IBA 06/2009
1	Tumor Viral Antigens (Large T Antigen)IBA 06/2009
1	OSU 03012IBA 06/2009
1	Drosophila merlinIBA 01/2008
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2008
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2008
1	Cyclin DIBA 03/2006
1	AntibodiesIBA 03/2006
1	Tumor Protein p73IBA 01/2006
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 12/2005
1	moesinIBA 12/2005
1	radixinIBA 12/2005
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 11/2003
1	Basic Helix-Loop-Helix Transcription FactorsIBA 11/2003
1	DNA (Deoxyribonucleic Acid)IBA 11/2003
1	Caspase 3 (Caspase-3)IBA 05/2003

Therapy/Procedure

9	Therapeutics 01/2021 - 02/2006
2	Drug Therapy (Chemotherapy) 01/2021 - 01/2018
1	Aftercare (After-Treatment) 01/2018
1	Radiotherapy 11/2017
1	Off-Label Use 11/2017
1	Molecular Targeted Therapy 11/2017